471 related articles for article (PubMed ID: 25056472)
21. Fascin expression in serous tumors of ovary correlates with aggressiveness of malignancy.
Wen YH; Yee H; Goswami S; Shukla PS
Int J Gynecol Pathol; 2009 Mar; 28(2):187-92. PubMed ID: 19188814
[TBL] [Abstract][Full Text] [Related]
22. Expression of GLUT-1 glucose transporter in borderline and malignant epithelial tumors of the ovary.
Cantuaria G; Magalhaes A; Penalver M; Angioli R; Braunschweiger P; Gomez-Marin O; Kanhoush R; Gomez-Fernandez C; Nadji M
Gynecol Oncol; 2000 Oct; 79(1):33-7. PubMed ID: 11006027
[TBL] [Abstract][Full Text] [Related]
23. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms.
Yakirevich E; Sabo E; Lavie O; Mazareb S; Spagnoli GC; Resnick MB
Clin Cancer Res; 2003 Dec; 9(17):6453-60. PubMed ID: 14695148
[TBL] [Abstract][Full Text] [Related]
24. [Correlation of hK6 expression with clinicopathological features and prognosis in epithelial ovarian cancer].
Hu CJ; Zhang F; Chen YJ; Sun XM; Zheng JF
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):520-3. PubMed ID: 19950700
[TBL] [Abstract][Full Text] [Related]
25. Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
Shibata K; Kajiyama H; Mizokami Y; Ino K; Nomura S; Mizutani S; Terauchi M; Kikkawa F
Gynecol Oncol; 2005 Jul; 98(1):11-8. PubMed ID: 15907336
[TBL] [Abstract][Full Text] [Related]
26. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma.
Zhang C; Wang YE; Zhang P; Liu F; Sung CJ; Steinhoff MM; Quddus MR; Lawrence WD
Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693
[TBL] [Abstract][Full Text] [Related]
27. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
28. High expression of tissue inhibitor of metalloproteinase-2 in serous ovarian carcinomas and the role of this expression in ovarian tumorigenesis.
Kim TJ; Rho SB; Choi YL; Choi CH; Lee JW; Bae DS; Ahn G; Lee JH; Kim BG
Hum Pathol; 2006 Jul; 37(7):906-13. PubMed ID: 16784992
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors.
Palazzo JP; Monzon F; Burke M; Hyslop T; Dunton C; Barusevicius A; Capuzzi D; Kovatich AJ
Hum Pathol; 2000 Jun; 31(6):698-704. PubMed ID: 10872663
[TBL] [Abstract][Full Text] [Related]
30. GLUT1 mRNA and protein expression in ovarian borderline tumors and cancer.
Rudlowski C; Moser M; Becker AJ; Rath W; Buttner R; Schroder W; Schurmann A
Oncology; 2004; 66(5):404-10. PubMed ID: 15331928
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
Brustmann H
Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study.
Brustmann H
Gynecol Oncol; 2005 Sep; 98(3):396-402. PubMed ID: 16005054
[TBL] [Abstract][Full Text] [Related]
33. Clinical and prognostic significance of lost or decreased PDCD5 expression in human epithelial ovarian carcinomas.
Zhang X; Wang X; Song X; Wei Z; Zhou C; Zhu F; Wang Q; Ma C; Zhang L
Oncol Rep; 2011 Feb; 25(2):353-8. PubMed ID: 21165576
[TBL] [Abstract][Full Text] [Related]
34. Expression of extracellular matrix proteins in ovarian serous tumors.
Salani R; Neuberger I; Kurman RJ; Bristow RE; Chang HW; Wang TL; Shih IeM
Int J Gynecol Pathol; 2007 Apr; 26(2):141-6. PubMed ID: 17413980
[TBL] [Abstract][Full Text] [Related]
35. [Expressions of Cx43 and Skp2 in epithelial ovarian tumor and their clinical significances].
Hu YQ; Liu YJ
Ai Zheng; 2005 Jan; 24(1):104-9. PubMed ID: 15642212
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
[TBL] [Abstract][Full Text] [Related]
37. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
38. p63 expression in epithelial ovarian tumors.
Poli Neto OB; Candido Dos Reis FJ; Zambelli Ramalho LN; Nogueira AA; de Andrade JM
Int J Gynecol Cancer; 2006; 16(1):152-5. PubMed ID: 16445626
[TBL] [Abstract][Full Text] [Related]
39. [Expression of SATB1 and BRMS1 in ovarian serous adenocarcinoma and its relationship with clinieopathological features].
Zhao XL; Wang P
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Jan; 42(1):82-5, 105. PubMed ID: 21355308
[TBL] [Abstract][Full Text] [Related]
40. Stage-specific embryonic antigen 4 expression in epithelial ovarian carcinoma.
Ye F; Li Y; Hu Y; Zhou C; Hu Y; Chen H
Int J Gynecol Cancer; 2010 Aug; 20(6):958-64. PubMed ID: 20683402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
